MAY 29, 2019 3:05 AM PDT

Novel Gene Therapy Approved by FDA to Treat Spinal Muscular Atrophy in Pediatric Patients

WRITTEN BY: Dena Aruta

The most common form of spinal muscular atrophy (SMA), a rare genetic disease, is caused by mutations of chromosome 5 in the gene, SMN1. SMN1 encodes for the protein, SMN, which translates to "survival of motor neuron." SMN appears to be responsible for the normal function of motor neurons in the spine that control voluntary muscle activity. Nearby SMN2 genes, depending on the number present, can partially compensate for the lack of SMN1 genes. There is also a rare form that is non-chromosome 5-linked SMA.

The majority of the symptoms these patients experience are related to muscle weakness in muscles near the center of the body (shoulders, thighs, upper back, hip). When the muscles involved in breathing and swallowing are affected, the prognosis is poor, resulting in death before two years of age. Due to the high variability in the age when symptoms begin, chromosome 5 SMA is broken down into four types ranging from mild to severe. Type 1 is seen at birth or in infancy and has the poorest prognosis. Types 2 and 3 develop during childhood and type 4 in teens and adults. Patients who develop SMA later in their teens or adulthood have milder and better motor functioning. The age of onset depends on the amount of functioning SMN the patient has, which correlates with the amount of SMN2 genes; the more functioning SMN, the later the onset.

There are currently no cures for SMA; however, on May 24, 2019, the FDA approved a novel gene therapy drug, Zolgensma, to treat SMA in children under two years of age. It is an adenovector-based gene therapy that targets the SMN1 gene and replaces it with a fully functioning copy into the affected motor neurons.

Figure 1. Example of Adenovector-Related Gene Therapy. Credit: National Human Genome Research Institute

Infants receiving this treatment require a one-time IV dose based on their weight. Its effectiveness has been evaluated in one completed clinical trial and one that is ongoing. Significant improvement in meeting milestones such as the ability to sit up without support has been reported in infants with SMA when compared to those not receiving the treatment.  The most common side effect is liver damage, which has to be monitored for at least three months after the procedure.

The FDA pushed Zolgensma through as a fast track, breakthrough therapy designated as priority review and an orphan drug. It also awarded the manufacturer, AveXis, Inc., with a rare pediatric disease voucher. There are few treatments available for some rare pediatric diseases, and these programs have been set up by the FDA to encourage research to find better treatments or cures for those diseases that currently have few options. 

 

 

About the Author
  • After earning my Bachelor of Science degree in biology/chemistry from Virginia Polytechnic Institute and State University (aka Va. Tech), I went on to complete clinical rotations in laboratory medicine at Roanoke Memorial Hospital. I spent the next 21 years working in healthcare as a clinical microbiologist. In 2015, I combined my fascination with medicine and passion for writing into a freelance career, and I haven't looked back. Even though my expertise is in microbiology and infectious diseases, I'm adept at writing about any medical topic. Being a freelance writer allows me to pursue a career where I can work at home with my two feline assistants, Luke and Grace. I'm a firm supporter of animal rights and volunteer for a local rescue during my free time. 
You May Also Like
OCT 04, 2020
Microbiology
A Virus Can Disrupt a Carb-Consuming Gut Microbe
OCT 04, 2020
A Virus Can Disrupt a Carb-Consuming Gut Microbe
Not all viruses affect animal cells; some viruses can infect bacteria. Humans are known to carry vast numbers of microor ...
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
OCT 12, 2020
Health & Medicine
How to Improve Your Online Teaching for the Pandemic
OCT 12, 2020
How to Improve Your Online Teaching for the Pandemic
The COVID-19 pandemic majorly disrupted education around the world. With many having had to learn the ins and outs of vi ...
OCT 20, 2020
Cardiology
Investigating a New Method in Heart Repair
OCT 20, 2020
Investigating a New Method in Heart Repair
Cardiovascular disease is a widespread issue that affects millions across the world. One of the most common of these dis ...
OCT 18, 2020
Cell & Molecular Biology
Small RNA is Connected to Bacterial Pathogenicity
OCT 18, 2020
Small RNA is Connected to Bacterial Pathogenicity
It's thought that as much as half of the global population carries a bacterium called Helicobacter pylori in their stoma ...
OCT 22, 2020
Health & Medicine
Vaping of Nicotine and Cannabis Mirror Each Other in Young People
OCT 22, 2020
Vaping of Nicotine and Cannabis Mirror Each Other in Young People
A new study has looked at whether nicotine and cannabis vaping follow similar trajectories from adolescence through to y ...
Loading Comments...